-
Science gets closer to understanding how a psychedelic trip changes the brain
Medical Mythbusting Commentary for May 6, 2026 Source:Science gets closer to understanding how a psychedelic trip changes the brain
-
PTSD leaves detectable marks in blood, new research reveals
Medical Mythbusting Commentary for April 29, 2026 Source:PTSD leaves detectable marks in blood, new research reveals Reference:Towards scalable biomarker discovery in posttraumatic stress disorder: triangulating genomic and phenotypic evidence from a health system biobank
-
Irritable Male Syndrome (IMS) Is Not An Actual Condition
Medical Mythbusting Commentary for April 7, 2026 Source:Irritable Male Syndrome (IMS) Is An Actual Condition — And It Could Explain A Lot Irritable Male Syndrome (IMS) is not a true, distinct medical condition in humans. The HuffPost article accurately summarizes symptoms (irritability, fatigue, low libido, mood changes) linked to gradual testosterone decline after age 40, citing…
-
Many caveats and confounding factors inherent in this study that claims irregular bedtime doubles cardiovascular disease risk.
Medical Mythbusting Commentary for April 2, 2026 Source:Irregular Bedtime Doubles Cardiac Risk Reference:Sleep timing irregularity in midlife: association with incident major adverse cardiac events and cardiovascular disease mortality over a 10-year follow-up
-
Vaping: Emerging harms health systems can’t ignore, How vaping product producers are preying upon your children with enticing marketing strategies.
Medical Mythbusting Commentary for March 16, 2026 Source:Vaping: Emerging harms health systems can’t ignore
-
Limited power study with negligible clinical significant reports low doses of lithium may slow verbal memory decline from Alzheimer’s
Medical Mythbusting Commentary for March 10, 2026 Source:Low doses of lithium may slow verbal memory decline from Alzheimer’s Reference:Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial
-
What is the evidence that GLP-1 medications such as Ozempic and Mounjaro might help treat addiction?
Medical Mythbusting Commentary for March 9, 2026 Source:What to know about how GLP-1 medications such as Ozempic and Mounjaro might fight addiction Reference:Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
-
New rapid five-day protocol application of transcranial magnetic stimulation brain for the treatment of treatment-resistant depression seems to be of equal efficacy of the standard six- week treatment cycle.
Medical Mythbusting Commentary for February 26, 2026 Source:New brain stimulation approach could treat depression in just 5 days Reference:Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression.